** Shares of Terns Pharmaceuticals rise ~6% to $6.5 premarket
** Co says its experimental drug to treat a type of blood cancer showed clinically meaningful responses in patients at two lowest dose levels
** The drug, TERN-701, showed no dose-limiting toxicities across three completed dose levels, and no side-effect-related dose reductions or discontinuations - TERN
** TERN plans to share additional safety and efficacy data in late 2025
** The initial data was above expectations and supported long-term use, according to BMO Capital analysts
** TERN-701 is being developed to treat heavily pre-treated patients with relapsed/refractory chronic myeloid leukemia
** Up to last close, shares down ~5% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。